They concluded that increasing anti-TNF doses is ineffective in patients with ADAb but appropriate in case of subtherapeutic drug concentration and proposed an algorithm for optimization of therapeutic strategy in IBD patients with loss of response to IFX based on ADAb and trough drug measurement [6]. This evidence concerns the gene TNF and inflammatory bowel disease.